Sonnet BioTherapeutics (SONN) Competitors $4.74 -0.39 (-7.60%) Closing price 04:00 PM EasternExtended Trading$4.76 +0.01 (+0.32%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. ZYBT, CGEN, TIL, HURA, LFVN, SKYE, BMEA, KLRS, EXOZ, and ZNTLShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Zhengye Biotechnology (ZYBT), Compugen (CGEN), Instil Bio (TIL), TuHURA Biosciences (HURA), Lifevantage (LFVN), Skye Bioscience (SKYE), Biomea Fusion (BMEA), Kalaris Therapeutics (KLRS), eXoZymes (EXOZ), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors Zhengye Biotechnology Compugen Instil Bio TuHURA Biosciences Lifevantage Skye Bioscience Biomea Fusion Kalaris Therapeutics eXoZymes Zentalis Pharmaceuticals Zhengye Biotechnology (NASDAQ:ZYBT) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Do insiders and institutionals hold more shares of ZYBT or SONN? 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 8.5% of Sonnet BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, ZYBT or SONN? Zhengye Biotechnology has higher revenue and earnings than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M5.03$1.55MN/AN/ASonnet BioTherapeutics$20K1,618.71-$7.44MN/AN/A Do analysts rate ZYBT or SONN? Sonnet BioTherapeutics has a consensus target price of $20.00, suggesting a potential upside of 321.94%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Sonnet BioTherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ZYBT or SONN more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Sonnet BioTherapeutics N/A -4,646.10%-342.21% Does the media favor ZYBT or SONN? In the previous week, Sonnet BioTherapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Sonnet BioTherapeutics and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.89 beat Sonnet BioTherapeutics' score of 0.63 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Zhengye Biotechnology Very Positive Sonnet BioTherapeutics Positive SummarySonnet BioTherapeutics beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.02M$3.38B$6.14B$10.66BDividend YieldN/A2.29%5.72%4.71%P/E RatioN/A21.3485.8427.65Price / Sales1,618.71486.46626.13140.50Price / CashN/A47.1938.3262.20Price / Book-6.6810.4313.066.79Net Income-$7.44M-$52.40M$3.30B$275.88M7 Day Performance-21.13%6.36%4.81%2.64%1 Month Performance51.92%16.14%9.99%9.13%1 Year Performance-4.24%33.90%85.28%35.89% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.371 of 5 stars$4.74-7.6%$20.00+321.9%+5.1%$35.02M$20K0.0010News CoverageAnalyst ForecastGap DownZYBTZhengye BiotechnologyN/A$2.72+24.2%N/AN/A$128.30M$186.36M0.00278Positive NewsCGENCompugen1.3827 of 5 stars$1.44-0.3%$4.00+178.7%+4.6%$127.61M$27.86M-6.5070News CoveragePositive NewsAnalyst ForecastGap DownTILInstil Bio3.3256 of 5 stars$18.50+0.2%$88.50+378.4%-42.3%$125.95MN/A-1.44410Positive NewsAnalyst ForecastHURATuHURA Biosciences1.6921 of 5 stars$2.50+1.0%$12.67+407.7%N/A$124.37MN/A0.00N/ANews CoveragePositive NewsAnalyst ForecastLFVNLifevantage4.3047 of 5 stars$9.76+0.0%$30.50+212.4%-22.8%$123.50M$228.53M13.15260Positive NewsAnalyst ForecastSKYESkye Bioscience2.5793 of 5 stars$3.92+1.0%$14.75+276.3%-55.6%$122.09MN/A-3.7211News CoverageAnalyst DowngradeAnalyst RevisionGap UpBMEABiomea Fusion3.3242 of 5 stars$2.04-1.2%$9.50+366.8%-85.3%$121.70MN/A-0.6750Positive NewsAnalyst ForecastOptions VolumeKLRSKalaris Therapeutics1.3698 of 5 stars$6.48+2.0%$3.00-53.7%N/A$121.18MN/A0.00110News CoverageAnalyst ForecastEXOZeXoZymes1.0099 of 5 stars$14.21-2.0%N/AN/A$119.22M$70K0.0029News CoverageAnalyst ForecastGap UpZNTLZentalis Pharmaceuticals1.7579 of 5 stars$1.58+5.7%$5.84+270.8%-46.1%$114.34M$67.43M-0.70160News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Zhengye Biotechnology Competitors Compugen Competitors Instil Bio Competitors TuHURA Biosciences Competitors Lifevantage Competitors Skye Bioscience Competitors Biomea Fusion Competitors Kalaris Therapeutics Competitors eXoZymes Competitors Zentalis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
